1. Metallo-Beta-Lactamase-Producing Multidrug-Resistant Acinetobacter Isolates in Patients with Ventilator-Associated Pneumonia
- Author
-
S. T. Mohite, Virendra C. Patil, and Harsha V. Patil
- Subjects
biology ,medicine.drug_class ,business.industry ,medicine.medical_treatment ,Antibiotics ,Ventilator-associated pneumonia ,chemical and pharmacologic phenomena ,General Medicine ,Acinetobacter ,bacterial infections and mycoses ,medicine.disease ,biology.organism_classification ,Intensive care unit ,Tertiary care ,General Biochemistry, Genetics and Molecular Biology ,Microbiology ,law.invention ,Pneumonia ,law ,medicine ,Beta-lactamase ,In patient ,business - Abstract
Background: Acinetobacter, a nonfermenting Gram-negative coccobacilli, have emerged as significant pathogens causing multidrug-resistant (MDR) ventilator-associated pneumonia (VAP). Metallo-beta-lactamase (MBL)-producing Acinetobacter spp. have become an emerging therapeutic concern worldwide due to the MDR isolates. Aim and Objectives: Phenotypic detection of MBL producing MDR Acinetobacter isolates in patients with VAP and to study the antibiotic susceptibility pattern of MBL-producing isolates. Materials and Methods: This was a prospective observational and noninterventional study conducted on patients with VAP over a period of 2 years. This study was conducted at a tertiary care teaching hospital in the intensive care unit. A total of 164 MBL-producing MDR AB isolates were included in the study. MBL was detected by imipenem-EDTA double-disc synergy test (DDST), imipenem-EDTA combined disc synergy test (CDST-IPM), and MBL-E test. Results: A total of 188 samples were enrolled for the study, fulfilling the inclusion criteria of VAP. Total MDR Acinetobacter spp. isolates were 188 (76.42%) of them, 164 (87.23%) were MBL producing and 24 (12.76%) were nonMBL (P
- Published
- 2021
- Full Text
- View/download PDF